Related references
Note: Only part of the references are listed.Intracranial Injection of Gammagard, a Human IVIg, Modulates the Inflammatory Response of the Brain and Lowers Aβ in APP/PS1 Mice Along a Different Time Course than Anti-Aβ Antibodies
Tiffany L. Sudduth et al.
JOURNAL OF NEUROSCIENCE (2013)
Diffusion of Macromolecules in the Brain: Implications for Drug Delivery
Daniel J. Wolak et al.
MOLECULAR PHARMACEUTICS (2013)
Properties of mouse and human IgG receptors and their contribution to disease models
Pierre Bruhns
BLOOD (2012)
Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
Frederique Bard et al.
EXPERIMENTAL NEUROLOGY (2012)
Interaction between intravenous immunoglobulin (IVIg) and the low-density lipoprotein receptor-related protein 1: A role for transcytosis across the blood brain barrier?
Dominic Paquin Proulx et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease
Isabelle St-Amour et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Mechanisms of Disease Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Erwin W. Gelfand
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Epidemiology of Alzheimer Disease
Richard Mayeux et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Qi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor
Sarah Paris-Robidas et al.
MOLECULAR PHARMACOLOGY (2011)
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Jasvinder K. Atwal et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Quantitative Analysis of the Interaction Strength and Dynamics of Human IgG4 Half Molecules by Native Mass Spectrometry
Rebecca J. Rose et al.
STRUCTURE (2011)
Dose-Related Induction of Hepatic Preneoplastic Lesions by Diethylnitrosamine in C57BL/6 Mice
Masahiko Kushida et al.
TOXICOLOGIC PATHOLOGY (2011)
Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid-beta
Karthikeyan Balakrishnan et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease
Johanna Magga et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction
Yulia Katsman et al.
TRANSFUSION (2010)
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease
Robert D. Bell et al.
ACTA NEUROPATHOLOGICA (2009)
Glycosylation as a strategy to improve antibody-based therapeutics
Roy Jefferis
NATURE REVIEWS DRUG DISCOVERY (2009)
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Norman R. Relkin et al.
NEUROBIOLOGY OF AGING (2009)
Blood-brain barrier: Ageing and microvascular disease-systematic review and meta-analysis
Andrew J. Farrall et al.
NEUROBIOLOGY OF AGING (2009)
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
H. Fillit et al.
NEUROLOGY (2009)
Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease
Fanchon Bourasset et al.
NEUROPHARMACOLOGY (2009)
Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease
Michael Bacher et al.
NEUROSCIENCE LETTERS (2009)
Pathophysiology of the blood-brain barrier: Animal models and methods
Brian T. Hawkins et al.
CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, VOL 80 (2008)
IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions
Signe Humle Jorgensen et al.
EXPERIMENTAL BRAIN RESEARCH (2007)
Insights into the mechanisms of action of anti-Aβ antibodies in Alzheimer's disease mouse models
Yona Levites et al.
FASEB JOURNAL (2006)
Similarity and divergence in the development and expression of the mouse and human antibody repertoires
HW Schroeder
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2006)
IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor
R Deane et al.
JOURNAL OF NEUROSCIENCE (2005)
Enhanced prospects for drug delivery and brain targeting by the choroid Plexus-CSF route
CE Johanson et al.
PHARMACEUTICAL RESEARCH (2005)
Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice
LM Billings et al.
NEURON (2005)
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition
DM Wilcock et al.
JOURNAL OF NEUROSCIENCE (2004)
The blood-brain barrier: an overview - Structure, regulation, and clinical implications
P Ballabh et al.
NEUROBIOLOGY OF DISEASE (2004)
Triple-transgenic model of Alzheimer's disease with plaques and tangles:: Intracellular Aβ and synaptic dysfunction
S Oddo et al.
NEURON (2003)
Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex (TM), 10%)
M Ballow et al.
VOX SANGUINIS (2003)
Passage of amyloid β protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease
WA Banks et al.
PEPTIDES (2002)
Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier
Y Zhang et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics
TS Raju et al.
GLYCOBIOLOGY (2000)